EMS
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS14
PHASE 3 / 2-314
RECRUITING6
READOUTS ≤12 MONTHS2
READOUT SLIPPED >6 MO83%
Delay Index: of 6 active trials registered more than a year ago, 5 have moved their primary completion (readout) date by more than 6 months since first registration (median +34.0 months). See all sponsors →
Open EMS on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| ALIV NCT06237231 |
P3 | Not yet recruiting | Moderate Pain; Severe Pain | 252 | 2025-03-15 |
| SIERRA NCT06272409 |
P3 | Not yet recruiting | Allergic Rhinitis | 318 | 2025-03-15 |
| Praga formulation NCT04666714 |
P3 | Recruiting | Neuropathic Pain | 136 | 2025-09-30 |
| Minoxidil + finasteride NCT04594018 |
P3 | Recruiting | Androgenetic Alopecia | 190 | 2026-05 (+37 mo) |
| DÁLIA NCT05886088 |
P3 | Not yet recruiting | Type 2 Diabetes Mellitus | 597 | 2026-05 |
| BERLIM 25/20 ASSOCIATION NCT04602754 |
P3 | Recruiting | Dyslipidemia Associated With Type II Diabetes Mellitus | 228 | 2026-05 (+30 mo) |
| AUSTRÁLIA NCT06264414 |
P3 | Not yet recruiting | Prostatic Hyperplasia, Benign; Erectile Dysfunction | 262 | 2026-06 |
| ASTRAL NCT05640232 |
P3 | Recruiting | Primary Dysmenorrhea | 238 | 2026-06-28 (+16 mo) |
| MADALENA ASSOCIATION NCT04670666 |
P3 | Recruiting | Type 2 Diabetes Mellitus | 270 | 2026-07 (+35 mo) |
| PIEMONTE NCT05028140 |
P3 | Recruiting | Type II Diabetes | 480 | 2026-07 (+34 mo) |
| GENERA NCT05824065 |
P3 | Not yet recruiting | Female Pattern Baldness | 504 | 2027-01 |
| LIBERTÀ NCT06268054 |
P3 | Not yet recruiting | Primary Dysmenorrhea | 78 | 2027-02 |
| DESPRIN NCT07835074 |
P3 | Not yet recruiting | Persistent Allergic Rhinitis | 316 | 2028-12 |
| TRÍADE-HA NCT07030101 |
P3 | Not yet recruiting | Hypertension | 400 | 2029-05 (+3 mo) |